ImmunityBio, Inc. (IBRX)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
7.85 USD
+0.05
(0.706%)
⇧
(July 14, 2026, 10:34 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:13 a.m. EDT
The immediate outlook is defined by a tense standoff between aggressive retail speculation and deep institutional hedging. While the stock has rallied significantly off its lows, the underlying business remains in a precarious state with negative free cash flow, a massive debt load relative to cash, and a history of severe multi-year declines. The recent price action is driven entirely by hope surrounding a specific clinical trial (Anktiva-NK) and potential index inclusion, rather than sustainable operational improvements. The options market confirms this fragility: traders are buying cheap calls for a speculative pop but have erected formidable put walls to protect against a return to the $4-$7 range. Until the company demonstrates a path to profitability or a definitive regulatory milestone that de-risks the pipeline, this remains a high-risk speculative vehicle where the odds favor a continued struggle to find a stable floor rather than a fundamental recovery. |
| Model | MAE |
|---|---|
| MSTL_79_115 ✓ | 0.068445 |
| AutoARIMA | 0.069433 |
| AutoETS | 0.069434 |
| AutoTheta | 0.069764 |
| MSTL | 0.069850 |
| MSTL_79 | 0.169383 |
| MSTL_115 | 0.197718 |
Forecast horizon: 60 days | Selected: MSTL_79_115
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 1.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.146 |
| Market Cap | 8,216,492,032 |
| Forward P/E | 130.75 |
| Beta | 0.08 |
| Website | https://immunitybio.com |
As of July 11, 2026, 4:13 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a decisive breakout. Call volume is heavily skewed toward out-of-the-money strikes (9.0 and 10.0), suggesting bets on a rally to the $10-$12 zone, while massive put open interest walls exist at 7.5 and 4.0, indicating a strong defense of the current floor. The disparity between high call volume and lower put volume suggests a bullish bias, but the heavy concentration of options at specific strikes implies the market expects a choppy grind rather than a free-fall or a moonshot.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8430657 |
| Address1 | 3,530 John Hopkins Court |
| All Time High | 45.42 |
| All Time Low | 0.93 |
| Ask | 9.83 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 12,470,960 |
| Average Daily Volume3 Month | 13,615,350 |
| Average Volume | 13,615,350 |
| Average Volume10Days | 12,470,960 |
| Beta | 0.077 |
| Bid | 5.66 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -0.831 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.845 |
| Current Ratio | 6.666 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.94 |
| Day Low | 7.65 |
| Display Name | ImmunityBio |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,785,846,600 |
| Earnings Timestamp Start | 1,785,846,600 |
| Ebitda | -245,412,992 |
| Ebitda Margins | -1.7408 |
| Enterprise To Ebitda | -36.28 |
| Enterprise To Revenue | 63.156 |
| Enterprise Value | 8,903,496,704 |
| Eps Forward | 0.06 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.8061 |
| Fifty Day Average Change | 0.0388999 |
| Fifty Day Average Change Percent | 0.004983269 |
| Fifty Two Week Change Percent | 184.30658 |
| Fifty Two Week High | 12.43 |
| Fifty Two Week High Change | -4.5850005 |
| Fifty Two Week High Change Percent | -0.36886567 |
| Fifty Two Week Low | 1.95 |
| Fifty Two Week Low Change | 5.8949995 |
| Fifty Two Week Low Change Percent | 3.0230765 |
| Fifty Two Week Range | 1.95 - 12.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,438,090,200,000 |
| Float Shares | 394,161,196 |
| Forward Eps | 0.06 |
| Forward P E | 130.75 |
| Free Cashflow | -193,704,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 684 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.99337995 |
| Gross Profits | 140,044,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.62473 |
| Held Percent Institutions | 0.17645 |
| Implied Shares Outstanding | 1,047,353,977 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California. |
| Long Name | ImmunityBio, Inc. |
| Market | us_market |
| Market Cap | 8,216,492,032 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_303022599 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -854,534,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,169,361,020 |
| Number Of Analyst Opinions | 3 |
| Open | 7.83 |
| Operating Cashflow | -294,390,016 |
| Operating Margins | -1.57877 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 844 696 5235 |
| Previous Close | 7.79 |
| Price Hint | 2 |
| Price To Book | -9.4404335 |
| Price To Sales Trailing12 Months | 58.282505 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.242 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.05499983 |
| Regular Market Change Percent | 0.7064846 |
| Regular Market Day High | 7.94 |
| Regular Market Day Low | 7.65 |
| Regular Market Day Range | 7.65 - 7.94 |
| Regular Market Open | 7.83 |
| Regular Market Previous Close | 7.79 |
| Regular Market Price | 7.845 |
| Regular Market Time | 1,784,039,664 |
| Regular Market Volume | 1,635,615 |
| Return On Assets | -0.34379002 |
| Revenue Growth | 1.676 |
| Revenue Per Share | 0.146 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 1,047,353,977 |
| Shares Percent Shares Out | 0.1259 |
| Shares Short | 131,830,884 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 132,143,163 |
| Short Name | ImmunityBio, Inc. |
| Short Percent Of Float | 0.3394 |
| Short Ratio | 9.91 |
| Source Interval | 15 |
| State | CA |
| Symbol | IBRX |
| Target High Price | 15.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 13.0 |
| Target Median Price | 12.0 |
| Total Cash | 380,879,008 |
| Total Cash Per Share | 0.364 |
| Total Debt | 1,124,608,000 |
| Total Revenue | 140,976,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.571825 |
| Two Hundred Day Average Change | 2.2731748 |
| Two Hundred Day Average Change Percent | 0.4079767 |
| Type Disp | Equity |
| Volume | 1,635,615 |
| Website | https://immunitybio.com |
| Zip | 92,121 |